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Introduction
At 17.6%, Botswana has one of the highest HIV preva-
lence rates globally. Tutume district, has a disproportio-
nately higher HIV prevalence at 20.7% (BAIS, 2008).
Only 54% of the infected actually know their HIV status.
The investigators set out to determine if increased
access to HIV testing and point-of-care CD4 testing can
minimize delays to ART initiation.
Materials and methods
Six ART-providing clinics were allocated 2 PIMA
machines each. The PIMA machines were validated
against the FACS Calibur machine as the instrument of
reference. Community mobilizers were identified for
each village. Door-to-door HCT and CD4 testing was
done. Community outreaches and HIV/CD4 testing in
schools, brick laying factories and mines were organized.
Road shows were conducted to attract youth to test.
External quality assurance was done quarterly. Data was
recorded on HCT registers and Point-of-Care CD4 regis-
ters and entered into CSPro database and analyzed using
STATA 10.0.
Results
A total of 6274 clients were tested for HIV in 3 months.
Of these, 62 % were new testers, while 501 clients tested
HIV positive (8%). Of these, 157 (31.3%) were enrolled on
ART. A total of 2717 CD4 tests were performed. Of these,
73.4% were conducted at home, or outreach sites. Majority
(65%) of the new testers were women aged 15- 49 years.
Youths preferred to test at night during moonlight testing.
There were no statistically significant differences in the
CD4+ T cell counts obtained using the PIMA with capil-
lary blood and those observed using FACS Calibur and
venous blood. The difference tended to be significant at
CD4+ T cell counts greater than 350 cell / µl (-21.2 (95%
CI -45.3, +2.9)) whereby the PIMA gave slightly lower
values than the FACS Calibur. Time from HIV testing to
ART-initiation was reduced from 6 to 3 weeks.
Conclusions
Point-of-care CD 4 testing has the potential to reduce
the time to ART initiation; thereby contributing to
reduction in morbidity and mortality. Youth-friendly
services can contribute to increased HCT uptake in this
age group.
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